weight loss drugs other than glp 1 GLP-1 Drugs: How Semaglutide & Tirzepatide Redefine Obesity Care Rx Trends: Real-World Data on
Description
Similarly, the discovery of a RAAS chronobiology could represent a milestone to change the paradigm of treatment of these pathologies
But the glamour has a hard edge
In this regard, the GIP and GLP-1 agonist, tirzepatide, currently shows promising data derived from phase 2 and 3 clinical trials
These evidence-based strategies come from clinical trial observations and experienced user reports
Obesity has been implicated as promoting cardiovascular disease, diabetes, hypertension, and other complications, suggesting that sustained, effective weight loss may have independent cardiovascular benefit [13] [14]
